First Turn Management’s Oric Pharmaceuticals ORIC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$25.6M Buy
2,017,284
+6,977
+0.3% +$79.2K 2.86% 14
2025
Q4
$16.4M Sell
2,010,307
-149,167
-7% -$1.72M 1.88% 25
2025
Q3
$25.9M Buy
2,159,474
+149,551
+7% +$1.57M 3.89% 12
2025
Q2
$20.4M Sell
2,009,923
-17,507
-0.9% -$118K 3.81% 9
2025
Q1
$11.3M Buy
2,027,430
+576,393
+40% +$5.04M 2.28% 22
2024
Q4
$11.7M Hold
1,451,037
2.1% 26
2024
Q3
$14.9M Sell
1,451,037
-64,923
-4% -$642K 2.35% 20
2024
Q2
$10.7M Buy
1,515,960
+418,389
+38% +$3.75M 1.74% 31
2024
Q1
$15.1M Buy
+1,097,571
New +$13M 2.26% 25

Other funds holding ORIC

First Turn Management's ORIC Position: Q1 2026 in Review

First Turn Management increased its Oric Pharmaceuticals (ORIC) stake by 0.35% in Q1 2026, buying an estimated $79.2K and bringing the position to 2,017,284 shares worth $25.6M. The position accounts for 2.86% of the portfolio, ranked #14.

First Turn Management first reported a position in ORIC in Q1 2024 and has held it in 9 quarters since. The position peaked at $25.9M in Q3 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • First Turn Management held 2,017,284 shares of Oric Pharmaceuticals worth $25.6M as of Q1 2026.
  • First Turn Management bought 6,977 Oric Pharmaceuticals shares in Q1 2026, an estimated $79.2K.
  • Oric Pharmaceuticals made up 2.86% of First Turn Management's portfolio in Q1 2026, its #14 holding.
  • First Turn Management first reported a position in Oric Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • First Turn Management's Oric Pharmaceuticals position peaked at $25.9M in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on First Turn Management's 13F filing for Q1 2026, filed 15 May 2026.